Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KYMR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKymera completes Phase 2b enrollment 6 months early, accelerates KT-621 data to year-end 2026
Filed June 25, 2026 · Period ending June 25, 2026 · ~1 min read
Key Changes
-
high
Completed enrollment in BROADEN2 Phase 2b trial of KT-621 for moderate to severe atopic dermatitis approximately 6 months ahead of schedule, moving topline data readout from mid-2027 to year-end 2026.
Item 8.01 — Other Events verify on EDGAR → -
high
Plans to initiate Phase 3 trials in atopic dermatitis by mid-2027, subject to regulatory discussions, representing an accelerated development timeline enabled by early Phase 2b completion.
Item 8.01 — Other Events verify on EDGAR → -
medium
BROADEN2 trial evaluates three doses of KT-621 in approximately 200 patients aged 12-75 over 16 weeks, with primary endpoint measuring percent change in EASI score at Week 16.
Exhibit 99.1 view on EDGAR → -
medium
KT-621 also being evaluated in separate BREADTH Phase 2b trial for moderate to severe eosinophilic asthma, with data expected in late 2027, expanding potential commercial opportunity.
Exhibit 99.1 view on EDGAR → -
medium
KT-621 has received FDA Fast Track designation for both moderate to severe atopic dermatitis and eosinophilic asthma, facilitating more frequent FDA interactions and potentially expediting review.
Exhibit 99.1 view on EDGAR →
Summary
Kymera Therapeutics completed patient enrollment in its Phase 2b BROADEN2 trial of KT-621, a first-in-class oral STAT6 degrader for moderate to severe atopic dermatitis, an undisclosed amount six months ahead of schedule. This acceleration moves the expected topline data readout from mid-2027 to year-end 2026, a meaningful timeline improvement for a clinical-stage company.
The faster-than-expected enrollment suggests strong patient interest in the trial and positions Kymera to potentially initiate Phase 3 trials by mid-2027, subject to regulatory discussions. For retail investors, the accelerated timeline reduces execution risk and brings potential commercialization closer.
KT-621 has FDA Fast Track designation for both atopic dermatitis and eosinophilic asthma (the latter being evaluated in a separate Phase 2b trial with late 2027 data expected), which could facilitate regulatory interactions. The near-term catalyst is the year-end 2026 data readout: positive efficacy and safety results would validate the STAT6 degrader approach and support advancement to Phase 3, while disappointing results could significantly impact the stock. Watch for any updates on the Phase 2b data quality or early signals as the readout approaches.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
KT-621 is also being evaluated in the ongoing BREADTH Phase 2b trial in moderate to severe eosinophilic asthma, with data expected to be reported in late 2027.
KT-621 is simultaneously being evaluated in a separate Phase 2b trial for moderate to severe eosinophilic asthma, with results expected in late 2027. This parallel development approach across multiple Type 2 inflammatory conditions expands the potential commercial opportunity for the drug candidate.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 25, 2026, the Company announced that it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (“AD”). Enrollment was completed in advance of prior expectations, and the Company expects this development to accelerate the timing of its anticipated topline data readout to year-end 2026, representing a potential advancement of six months relative to its prior expectation of releasing the readout in mid-2027.
Kymera completed patient enrollment in its Phase 2b trial of KT-621 for moderate to severe atopic dermatitis ahead of schedule. This accelerates the expected topline data release by six months, from mid-2027 to year-end 2026. Faster enrollment suggests strong patient interest and could expedite the drug's path to market.
Added in current filing · verify on EDGAR →
Subject to discussions with regulators, the Company expects to initiate Phase 3 trials in AD by mid-2027.
Kymera plans to begin Phase 3 trials for KT-621 in atopic dermatitis by mid-2027, pending regulatory discussions. This timeline positions the company to potentially advance toward commercialization within the next 12-18 months if Phase 2b results are positive.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 25, 2026 · How we verify